title: Overdose of pegfilgrastim: case report.
abstract: BACKGROUND
  Pegfilgrastim is a G-CSF that can be administered in a single dose 24 h after each cycle of chemotherapy.
  
  
  METHODS
  59 years-old man with a stage III-B peripheral T lymphoma with CD4 expression. Dose-dense chemotherapy was started with CHOP-14 combined with pegfilgrastim as primary prophylaxis. An error in the dispensing system meant that the patient received pegfilgrastim for 4 consecutive days. He remained under observation in hospital. During the 3 days after the last dose of pegfilgrastim, the patient remained stable, with no remarkable symptoms or associated laboratory abnormalities, and was discharged.
  
  
  CONCLUSIONS
  The case we describe and the available literature lead us to suggest close monitoring as the main measure to be adopted when treating a patient for pegfilgrastim overdose.
authors: Pharmacy Service, Hospital Clínic de Barcelona, c/Villarroel, 170, Escalera 8 sótano, 08036 Barcelona, Spain. gisbcn@hotmail.com
authors: Gisela
authors: G
authors: Riu
authors: Anna
authors: A
authors: Estefanell
authors: Meritxell
authors: M
authors: Nomdedeu
authors: Natàlia
authors: N
authors: Creus
mesh_terms: D062787:Drug Overdose; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008508:Medication Errors / Q000009:adverse effects*; D008875:Middle Aged; D009503:Neutropenia / Q000097:blood / Q000188:drug therapy; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim